DGAP-Adhoc: euromicron AG: According to the preliminary

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 13, 2014 at 8:15 AM

DGAP-Adhoc: euromicron AG: According to the preliminary business figures that have been presented, the company will achieve its targets in the adjusted guidance it issued on December 4, 2013 - No dividend pyment envisaged for 2013

euromicron AG / Key word(s): Final Results 13.03.2014 13:11 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Frankfurt/Main, March 13, 2014 - euromicron AG will fulfill the targets specified in the adjusted guidance it issued on December 4, 2013, following a difficult 4th quarter of 2013. On the basis of what is known at present and the unaudited figures, the Executive Board expects consolidated sales of just under EUR330 million (guidance: EUR320 million) and a consolidated EBITDA of around EUR14.5 million (guidance: just under 5%). In the core year of integration 2013, the company spend around EUR5.5 to 6 million from its operating income on investments and integration in order to shed and restructure personnel, to reorganize its divisions and on a raft of cost-cutting measures, and also had to cope with operational effects from shifts in earnings due to postponements in the call-off of deliveries and extra project costs. The effects of these measures in terms of cash and the balance sheet will not have any notable impact on the company's current liquidity situation and so on financing of its development. In view of the Group's earnings performance in 2013 and the anticipated net loss at euromicron AG, the Executive Board intends to propose to the General Meeting that no dividend be paid for 2013. After a strong start to 2014, the Executive Board sees, as expected, a cautiously positive performance for the upcoming phase of restructuring and, as part of the Agenda 500, is aiming to grow sales to EUR340-360 million and post an EBITDA margin of around 6-8% in 2014. The Executive Board is convinced that, following 10 years of growth and strong earnings, the cost-intensive integration and investment measures at the Group to enable it to grow its sales further to the goal of EUR500 million are necessary and correct to ensure shareholder value in the long-term future. euromicron AG (www.euromicron.de) is an all-round solution provider for communications, transport, data and security. euromicron's network infrastructures integrate voice, video and data transport wirelessly, via copper cable and by means of fiber-optic technologies. euromicron builds leading applications, such as security, control, healthcare or surveillance systems, on the basis of these cutting-edge network infrastructures. Founded on its expertise as a developer and producer of fiber-optic components, euromicron AG is a strongly growing, highly profitable group that is listed on the stock market, has a medium-sized character and focuses on operational growth, integration and further market penetration, internationalization and expansion. Contact: euromicron AG Investor & Public Relations Zum Laurenburger Hof 76 60594 Frankfurt/Main Germany Phone: +49 (0)69-631583-0 Fax: +49 (0)69-631583-17 E-mail: IR-PR@euromicron.de http://www.euromicron.de Securities identification number A1K030 ISIN DE000A1K0300 13.03.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: euromicron AG Zum Laurenburger Hof 76 60594 Frankfurt am Main Germany Phone: +49(0) 69 631583-0 Fax: +49(0) 69 631583-17 E-mail: info@euromicron.de Internet: www.euromicron.de ISIN: DE000A1K0300 WKN: A1K030 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Planning Your Pergola: DIY Backyard Transformation

Blueprint for a Backyard Upgrade Transforming a backyard isn't just about nailing down the aesthetics with a motorized pergola. The real magic is in thoughtful planning—right from the get-go. Whether you've got your sights set on the sleek FlexPatio motorized pergola kits or another setup, it all begins with a mental blueprint before a single speck of dirt is disturbed....

Renue Hawaii Ups Carpet Cleaning Game for Holidays

The Stakes of Carpet Care in Hawaii's Resorts Ah, Hawaii—the land of breathtaking beaches, vibrant luaus, and plush hotel carpets that take a beating every peak travel season. But before you brush off carpet care as mundane as a hollow coconut, let’s talk serious business. Renue Hawaii isn't fooling around with some one-size-fits-all cleaning routine. They’ve just...

Truecaller's Strategic Shift: Recovery and Growth in 2026

Grappling with Numbers: Truecaller's Q3 2026 Results A glance at Truecaller's latest report tells us they're banking on a strategic recovery.AOver their recent interim report covering January to September 2026, they disclose a modest 1% decrease in net sales reaching SEK 464 million. Now, if you scoop away the currency fluctuations, net sales climb by a soft 3% from Q2....

JLL Snaps Up Prime Boston Warehouse for $36M

Diving Deep into JLL's Latest Acquisition If you blinked, you might have missed JLL Income Property Trust's latest power move. These folks just laid down $36 million for a prime 54,000-square-foot Class A distribution hub in Northborough, Massachusetts. This isn't just any run-of-the-mill facility; it's 100% leased to a heavy-hitting tenant for the next 14 years with neat...

Hospitals Face $392M Squeeze Under Medicare's CJR-X

Medicare's CJR-X Challenges Hospitals 2028 is setting up to be a year hospitals across the U.S. remember, not with a smile, but likely with clenched teeth. Medicare's CJR-X model is ready to put about 2,217 hospitals in a financial vise over hip, knee, and ankle replacements. Going into effect on January 1, 2028, this mandate turns health networks' profit dreams into a...

Quarterhill's Q3 2026 Call Teases Insight into ITS Growth

The clock's ticking down to November 10, and eyes are peeled for Quarterhill's Q3 financial debrief. Why the fuss? Well, they’ve made quite a name for themselves in the Intelligent Transportation System (ITS) scene, tossing AI into the mix to boot. If you’re playing in this space—or just sneaking a peek to see where tech’s steering us next—you might want to dial...

Scientific Games Dives Into Omnichannel Lottery Future

Scientific Games Breaks New Ground at WLS 2026 Innovation isn't about resting on your laurels, and boy, does Scientific Games know it. At the World Lottery Summit in Sydney this November, they're showcasing a buffet of cutting-edge games and technology aimed at revolutionizing the lottery landscape. But hey, this ain't just about flashy lights and digital frills –...

Leidos Gears Up for Major U.S. Cruise Missile Push

Leidos Sets Sights on Boosting U.S. Missile Production There's big news out of Reston, Virginia, that should make investors sit up and take notice. Leidos (NYSE: LDOS) is revving up the supply chain engines to churn out thousands of long-range cruise missiles, specifically the new Low-Cost Containerized Missile (LCCM) and the combat-time-tested AGM-190A Havoc Spear...

DUPR Teams Up with InBody to Elevate Pickleball Fitness

Well, here's a twist in the pickleball world—DUPR and InBody have struck a deal to bring top-notch body composition tech to the ever-expanding universe of pickleballers. They're merging power players from two different worlds to tap into your performance on the court and your wellness off it. Maybe I'm just jaded from too many marketing pitches, but this one could...

Neurocrine Biosciences Hits $1 Billion Mark in Q3 2026

Neurocrine's Triple-Digit Surge Neurocrine Biosciences is on a tear, pushing its revenue up to a jaw-dropping $1.1 billion in Q3 2026—a hefty 41% leap from the previous year. Frankly, you can't ignore those numbers. INGREZZA, which is practically becoming a cash cow, did $801 million alone, rising 17% year over year. This rides the wave of prescription surges and solid...